The Food and Drug Administration (FDA) has issued warning letters to 30 telehealth companies for selling "illegal" compounded GLP-1s. The companies allegedly made false or misleading claims about their products, including that they were identical or similar to FDA-approved ones. The warning comes as part of a broader effort to clamp down on the sale of unapproved medications. Despite the current shortage of GLP1, companies like Hims & Hers have continued to sell compounded versions of the drug. The Department of Health and Human Services has referred Hims and Hers to the Department of Justice for potential criminal violations.